FRINGE
Contact us
At its heart are chemical agents (photosensitisers – PS) which preferentially accumulate in the tumours especially in brain cancers where the blood brain barrier is compromised. The PSs designed for FRINGE will contain metal centres like Gadolinium (Gd), to enable interaction with incoming neutrons and facilitate the transfer of neutron energy into electron excitation of the PS, confirmed by concomitant fluorescence emission. Interaction with ambient oxygen will generate reactive oxygen species which will kill the tumour cells. The main scientific break-through of this project will be to establish experimental proof-of-principle of this novel neutron-activated therapy.
FRINGE will combine the advantages of photomedical therapies (no mutagenic radiation) with the advantages of neutron-based therapies (large penetration depth). The externally applied neutron beam can be energy-tuned to become therapeutic exactly at the depth of the tumour. Exploiting Gd as a contrast agent, FRINGE can also become a theranostic modality by use of magnetic resonance imaging. FRINGE has the potential of causing immunogenic cell death to cancers which could eliminate occult metastasis and act as a ‘cancer vaccine’. The highly interdisciplinary project team comprises world renowned experts from a unique combination of disciplines: Nuclear physicists, synthetic chemists, photochemists, photobiologists, medical physicists, quantum chemists and radio-oncologists will join forces to lay the foundations for a novel, curative cancer therapy.
The project is sponsored by EUs Horizon 2020, the FET-OPEN program, and budget from H2020 to IFE is 560 000 Euro for a period of 4.5 years.
IFE is partner in the project and Oslo Universitetsykehus (OUS, Norway) has the project management. Other partners are NCSRD (Greece), Girona University (Italy), Synthetica AS (SYN, Norway), VSCHT (Czech Republic) and Valencia University (UPV, Spain).